Seven-membered ring scaffolds for drug discovery: Access to functionalised azepanes and oxepanes through diazocarbonyl chemistry by Nortcliffe, Andrew & Moody, Christopher J.
Seven-membered r ing scaffolds for drug discovery: Access to 
functionalised azepanes and oxepanes through diazocarbonyl 
chemistry. 
 
Andrew Nortcliffe and Christopher J. Moody* 
 
School of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, UK 
 
Corresponding author. Tel.: +44 115 846 8500; fax: +44 115 951 3564; e-mail address: 
c.j.moody@nottingham.ac.uk (C.J. Moody). 
 
 
Key-words:  
 
Seven-membered rings 
Azepane 
Oxepane 
Diazocarbonyl 
Medicinal Chemistry 
 
Graphical Abstract 
 
 
 
Abstract: 
 
Functionalised azepane and oxepane scaffolds were prepared using diazocarbonyl 
chemistry and elaborated to show their potential use in library synthesis. Key 
dicarbonyl containing seven-membered rings were functionalised via 
diastereoselective Luche reduction of the ketone followed by manipulation of the 
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ester and amine groups. Further scaffolds could be accessed by C-alkylation of the 
dicarbonyl compounds. In addition, an oxepane containing amino acid could be 
prepared via a diastereoselective enamine reduction. 
 
 
1. Introduction 
 
Seven-membered ring heterocycles are widely found in both natural products and 
medicinally active molecules. These include the azepanes claviciptic acid, 
imipramine and balanol, and the oxepanes (+)-isolaurepan, doxepin and 
hemibrevetoxin B (Figure 1).1  
 
 
Figure 1: Azepane and oxepane containing natural products and pharmaceuticals. 
 
Azepanes feature in the top 100 frequently used ring systems in small molecules,2 
with the dibenzazepine scaffold featuring in a wide number of analgesic and 
antipsychotic agents.3,4 Synthetic methods towards the synthesis of azepane 
containing scaffolds have garnered significant attention,5,6 with a wide range of 
reported methodologies for their preparation, including ring-closing metathesis,7 ring-
expansion,7,8 halo-cyclisation9 and intramolecular reductive amination.10 Oxepane 
scaffolds are widely found in polyether containing natural products such as the 
brevetoxin11,12 and ciguatoxin families.13,14 Relative to five- and six-membered oxygen 
containing heterocycles, oxepanes are synthetically more challenging due to 
enthalpic and entropic constraints.15–17 Methods towards oxepanes are diverse,5,6,18 
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with recent notable examples including organocatalytic intramolecular oxa-conjugate 
addition,19 iron(III) catalysed Prins cyclisation,20 and ring-closing ene-yne 
metathesis.21 
Seven-membered rings are often flanked by aromatic ring systems and these bi- and 
tricyclic systems have interesting activity on the central nervous system.1 However, 
this type of scaffold adds significant sp2 character to the overall compound. In an 
effort to synthesise scaffolds rich in sp3 character we report the preparation of 
azepane and oxepane cores through diazocarbonyl chemistry.  
 
2. Results and discussion 
 
Diazo compounds have attracted great interest in organic synthesis due to their 
versatility as synthetic intermediates.22 The diazo group can easily be introduced into 
activated methylene groups via Regitz diazo-transfer using sulfonyl azides as the 
transfer reagent.23 Diazocarbonyl compounds generated by this method are bench 
stable with predictable reactivity that can be attuned to the synthetic task at hand. 
The main synthetic feature is the generation of a carbene or metal carbenoid to 
generate a reactive intermediate that undergoes a wide range of C-H and X-H 
insertions (X = O, N, S, Si, P). These insertion reactions provide a valuable 
disconnection in organic synthesis. Diazoalkanes are also used in the Lewis acid-
catalysed ring expansion of cyclic ketones24,25 that proceed via a Tiffenau-Demjanov-
type intermediate, wherein the loss of molecular nitrogen drives the one-carbon ring 
expanded cyclic ketone. 
Herein, we report the synthesis of an azepane and oxepane scaffold using these two 
aspects of diazocarbonyl chemistry as the key steps for the generation of the seven-
membered ring. In addition, we describe the synthetic manipulation of these 
structures to allow for further structural elaboration suitable for the preparation of 
compound libraries. 
 
 
 
2.1 Azepane scaffold 
 
The Tiffeneau-Demjanov-type ring expansion of N-Boc-piperidone 1 to the 
corresponding dicarbonyl azepane 2 is widely documented in the literature.8 
However, the use of 2 has generally been restricted to its reactions as a 1,3-
dicarbonyl building block for the preparation of spirocyclic hydantion,26 fused 
pyrimidine27 or pyrazolone scaffolds.28 We sought to use azepane 2 as core scaffold 
with no further ring fusion.  
In our hands, the ring expansion of 1 provided the desired azepane 2 in 85% without 
the need for chromatographic purification (Scheme 1). Diastereoselective reduction 
of the ketone under Luche conditions at -78 °C furnished the syn-β-ketoalcohol 3 in 
62% in a 19:1 ratio of separable diastereomers (Scheme 1).29 Alcohol 3 exists in two 
ring conformers which readily invert on the NMR timescale. This ring inversion 
results in complication of the NMR spectra for this compound and later compounds in 
this series. Attempts to O-alkylate the alcohol 3 using NaH or Ag2O as a base with 
MeI or BnBr were unsuccessful, as was benzylation using benzyl 
trichloroacetimidate/TfOH. Methylation was accomplished using trimethyloxonium 
tetrafluoroborate and proton sponge to afford the methyl ether 4 in 81% yield 
(Scheme 1). Ester hydrolysis and subsequent amide formation with dimethylamine 
as a model amine furnished the amide 6 in 90% yield (Scheme 1). Deprotection of 
the tert-butoxycarbonyl group with hydrochloric acid with subsequent amide 
formation or sulfonylation provided the elaborated scaffolds 7 and 8 (Scheme 1). 
 
 
N
O
Boc
N
Boc
O O
OEt
N
Boc
RO O
OEt
N
Boc
MeO O
OHa b d
1 2  3 R = H  5
 4 R = Me c
e
N
Boc
MeO O
NMe2
f, h
 6
f, g
N
S
MeO O
NMe2
N
MeO O
NMe2
 7  8
O
BrBr
O
O
 Scheme 1: Synthesis of compounds 2-8. Reagents and conditions: (a) ethyl diazoacetate, BF3.OEt2, 
Et2O, -20 °C to 0 °C, rt, 3 h, 85%; (b) NaBH4, CeCl3.7H2O, MeOH, -78 °C, 1 h, 62%; (c) 
trimethyloxonium tetrafluoroborate, proton sponge, CH2Cl2, 0 °C to rt, 16 h, 81%; (d) LiOH, 
THF:MeOH:H2O, 0 °C to rt, 16 h, 82%; (e) dimethylamine hydrochloride, HATU, iPrNEt2, DMF/CH2Cl2 
(1:1), 0 °C to r.t, 16 h, 90%; (f) 4M HCl/dioxane solution, CH2Cl2, rt, 16 h, quant.; (g) 4-bromobenzoic 
acid, HATU, iPrNEt2, DMF/CH2Cl2 (1:1), 0 °C to r.t ,16 h, 50%; (h) 4-bromobenzenesulfonyl chloride, 
pyridine, NEt3, CH2Cl2, 0 °C to r.t, 16 h, 96%. 
 
Azepane 2 also underwent C-alkylation using caesium carbonate and iodomethane 
to provide the quaternary carbon centre in ester 9 (Scheme 2). Following similar 
steps as previously described, Luche reduction provided syn-alcohol 10 in a 9:1 ratio 
of separable diastereomers (Scheme 2).29 Ester hydrolysis of alcohol 10 provided 
carboxylic acid 11, which was effectively transformed into the dimethylamide 12 in 
50% yield (Scheme 1). Deprotection of the Boc-group of dimethylamide 12 with HCl 
provided the desired amine which underwent sulfonylation to give brosylate 13 in 
55% yield (Scheme 2). 
 
 
 
 
Scheme 2: Synthesis of compounds 9-13. Reagents and conditions: (a) MeI, Cs2CO3, DMF, 0 °C to 
r.t, 16 h, 92%; (b) NaBH4, CeCl3.7H2O, MeOH, -78 °C, 1 h, 62%; (c) LiOH, dioxane:H2O, reflux, 16 h, 
quant.; (d) dimethylamine hydrochloride, HATU, iPrNEt2, DMF/CH2Cl2 (1:1), 0 °C to r.t, 16 h, 50%; (e) 
4M HCl/dioxane solution, CH2Cl2, rt, 16 h, quant.; (f) 4-bromobenzenesulfonyl chloride, pyridine, NEt3, 
CH2Cl2, 0 °C to r.t, 16 h, 55%. 
 
Similarly, methylation of alcohol 10 with trimethyloxonium tetrafluoroborate/proton 
sponge furnished the desired methyl ether 14 in 77% yield (Scheme 3). Methyl ether 
14 underwent the same transformation to provide acid 15 and dimethylamide 16 
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(Scheme 3). Treatment of 16 with HCl resulted in deprotection of the dimethylamide 
along with the tert-butoxycarbonyl group, this was confirmed by brosylation to give 
the acid 17 (Scheme 3). Selective Boc deprotection was accomplished by reaction 
with trifluoroacetic acid (Scheme 3) followed by amide formation, reductive amination 
or sulfonylation to provide compounds 18, 19 and 20 respectively (Scheme 3). 
 
 
 
Scheme 3: Synthesis of compounds 14-20. Reagents and conditions: (a) trimethyloxonium 
tetrafluoroborate, proton sponge, CH2Cl2, 0 °C to rt, 16 h, 81%; (b) LiOH, dioxane:H2O, reflux, 16 h, 
quant.; (c) dimethylamine hydrochloride, HATU, iPrNEt2, DMF/CH2Cl2 (1:1), 0 °C to r.t, 16 h, 72%; (d) 
4M HCl/dioxane solution, CH2Cl2, rt, 16 h, quant.; (e) 4-bromobenzenesulfonyl chloride, pyridine, NEt3, 
CH2Cl2, 0 °C to r.t, 16 h, 45%; (f) TFA, CH2Cl2, rt, 3 h, quant.; (g) 4-bromobenzoic acid, HATU, iPrNEt2, 
DMF/CH2Cl2 (1:1), 0 °C to r.t ,16 h, 50%; (h) 4-bromobenzaldehyde, Na(OAc)3BH, 1,2-dichloroethane, 
0 °C to r.t, 16 h, 62%; (i) 4-bromobenzenesulfonyl chloride, pyridine, NEt3, CH2Cl2, 0 °C to r.t, 16 h, 
40%. 
 
2.2 Oxepane scaffold 
 
The key oxepane scaffold 23 was prepared via an intramolecular carbene O-H 
insertion. The precursor diazocarbonyl compound 22 has previously been reported 
through the addition of lithiated ethyl diazoacetate to δ-valerolactone 21.30 In our 
hands this proved difficult to replicate on decagram scale, and therefore we chose to 
follow the “one-pot” addition-diazotransfer reported by Chen et al.31 This proceeded 
in 78% over 2 steps on a 10 g scale (Scheme 4). Intramolecular O-H insertion was 
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effected using rhodium(II) acetate in dichloromethane to provide oxepane dicarbonyl 
ether 23 in 75% on a multigram scale (Scheme 4).30 Ether 23 was of sufficient purity 
to be carried onto next step without the need for further purification. Luche reduction 
(CeCl3/NaBH4) provided the alcohol as a 2:1 mixture of diastereomers (Scheme 4),29 
with the syn-alcohol 24 being isolated in 53% yield after chromatography. 
Interestingly, alcohol 24 exists as a single conformer on the NMR timescale. 
Methylation with trimethyloxonium tetrafluoroborate/proton sponge gave methyl ether 
25 in 87% yield (Scheme 4).  
 
 
 
Scheme 4: Synthesis of compounds 22-25. Reagents and conditions: (a) i. LDA, THF, -78 °C, 0.5 h, 
ii. EtOAc, -78 °C, 0.5 h, iii. lactone 21, -78 °C, 2 h; (b) p-acetamidobenzenesulfonyl azide, Et3N, 
CH3CN, -0 °C, 16 h, 78%; (c) Rh2(OAc)4, CH2Cl2, rt, 1.5 h, 75%; (d) NaBH4, CeCl3.7H2O, MeOH, -78 
°C, 1 h, 53%; (e) trimethyloxonium tetrafluoroborate, proton sponge, CH2Cl2, 0 °C to rt, 16 h, 87%. 
 
Subsequent hydrolysis of esters 24 and 25 provided the corresponding carboxylic 
acids 26 and 27 respectively (Scheme 5). Functionalisation of these scaffolds via an 
amide provides a point of further molecular diversity. This was exemplified by 
formation of the 4-bromobenzylamides 28 and 29 in 88 and 77% yield (Scheme 5). 
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Scheme 5: Synthesis of compounds 26-29. Reagents and conditions: (a) LiOH, THF:MeOH:H2O, 0 °
C to rt, 16 h, 26 =  quant, 27 = quant; (b) 4-bromobenzylamine hydrochloride, HATU, iPrNEt2, DMF, 0 
°C to r.t, 16 h, 28 = 77%, 29 = 88%. 
 
As with the azepane scaffold, a quaternary centre could be accessed by the C-
alkylation of oxepane 23 with caesium carbonate and iodomethane providing 
oxepane 30 in 62% yield on a multigram scale (Scheme 6). Subsequent Luche 
reduction furnished the alcohol 31 as an inseperable mixture of diastereomers (15:1 
ratio) in quantitative yield (Scheme 6).29 Methylation with Meerweins salt gave the 
methyl ether 32 in 88% (15:1 dr) (Scheme 6). Subsequent hydrolysis of esters 31 
and 32 was undertaken with lithium hydroxide providing carboxylic acids 33 and 34 
(15:1 dr) (Scheme 6). Elaboration as the amides was carried out using 4-
bromobenzylamine and HATU. The desired amides 35 and 36 were isolated in 
excellent yield as single diastereomers (Scheme 6). 
 
 
 
Scheme 6: Synthesis of compounds 30-36. Reagents and conditions: (a) MeI, Cs2CO3, DMF, 0 °C to 
r.t, 16 h, 62%; (b) NaBH4, CeCl3.7H2O, MeOH, -78 °C, 1 h, quant., 15:1 dr; (c) trimethyloxonium 
tetrafluoroborate, proton sponge, CH2Cl2, 0 °C to rt, 16 h, 88%, 15:1 dr; (d) LiOH, dioxane:H2O, reflux, 
16 h, 33 =  quant, 15:1 dr, 34 = quant, 15:1 dr; (e) 4-bromobenzylamine hydrochloride, HATU, iPrNEt2, 
DMF, 0 °C to r.t, 16 h, 35 = 92% (OH), 36 = 80% (OMe). 
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The β-ketoester oxepane 23 could additionally be converted to Boc-protected amino 
acid 37 (Scheme 7). Treatment of dicarbonyl compound 23 with ammonium acetate 
generated the enamine that was immediately reduced with sodium cyanoborohydride 
to generate the amine (Scheme 7).32,33 Boc-protection of the amine with di-tert-butyl 
dicarbonate provided the syn-Boc-protected amino acid 37 in a 64% yield over 3 
steps in 6.5:1 diastereomeric ratio with the trans-isomer (Scheme 7). Ester hydrolysis 
with lithium hydroxide gave the carboxylic acid 38 in quantitative yield (6.5:1 dr) 
(Scheme 7). HATU mediated amide coupling of acid 38 with benzylamine gave the 
amide 39 in 70% yield as a single diastereoisomer (Scheme 7). tert-Butoxycarbonyl 
deprotection could be accomplished using HCl or trifluoroacetic acid followed by 
amide formation, reductive amination and sulfonylation to provide compounds 40, 41 
and 42 in excellent yield (Scheme 7). 
 
 
 
Scheme 7: Synthesis of compounds 37-42. Reagents and conditions: (a) ammonium acetate, MeOH, 
r.t, 16 h; (b) NaBH3CN, AcOH, THF, 0 °C, 1 h; (c) Boc2O, Et3N, CH2Cl2, r.t, 16 h, 64% over 3 steps; (d) 
LiOH, THF:MeOH:H2O, r.t, 16 h, quant, 6.5:1 dr; (e) benzylamine, HATU, iPrNEt2, DMF, 0 °C to r.t, 16 
h, 70%; (f) 4M HCl/dioxane solution, CH2Cl2, r.t, 3 h, quant; (g) TFA, CH2Cl2, r.t, 3 h, quant; (h) (g) 4-
bromobenzoic acid, HATU, iPrNEt2, DMF (1:1), 0 °C to r.t, 16 h, 94%; (h) 4-bromobenzaldehyde, 
Na(OAc)3BH, 1,2-dichloroethane, 0 °C to r.t, 16 h, 82%; (i) 4-bromobenzenesulfonyl chloride, pyridine, 
NEt3, CH2Cl2, 0 °C to r.t, 16 h, 98%. 
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3. Conclusion 
 
We have developed a series of azepane and oxepane scaffolds through the use of 
diazocarbonyl chemistry to construct the seven-membered ring. The scaffolds can be 
further elaborated and functionalised to allow for the preparation of compound 
libraries containing seven-membered rings. 
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5. Supplementary information 
 
Full experimental details and NMR spectra for all compounds are provided in the 
Supplementary Information. 
 
6. General Experimental Procedures 
 
C-alkylation 
To a solution of β-ketoester (1 equiv.) in dry DMF at 0 °C, was added caesium carbonate 
(1.05 equiv.) and stirred for 15 min. Methyl iodide (2.5 equiv) was added slowly. The solution 
was allowed to warm to room temperature and stirred for 15 h. The solution was concentrated 
in vacuo and diluted with ether and water. The organic layer was separated and the aqueous 
layer extracted with ether). The organic layers were combined and washed with aqueous 
ammonium chloride (saturated) and brine. The organics were dried over MgSO4, filtered and 
the solvent removed under reduced pressure to yield the desired quaternary alkylated 
product. 
 
Luche reduction  
To a solution of β-ketoester (1 equiv.) in dry methanol was added CeCl3.7H2O (1.05 equiv.) 
and cooled to -78 °C. Sodium borohydride (0.7 equiv.) was added in small portions. Upon 
complete addition the solution was stirred for a further hour at -78 °C. The reaction was 
quenched with aqueous hydrochloric acid (2M) and warmed to room temperature. The 
reaction mixture was extracted with ether. The organic layers were combined and washed 
with brine, dried over Na2SO4, filtered and the solvent removed under reduced pressure. The 
crude residue was diluted with dichloromethane and evaporated onto silica gel. Purification by 
silica gel chromatography, eluting with ethyl acetate and light petroleum (5:95 to 15:85), 
provided the desired alcohol 
 
Methylation with Meerwein Salt 
To a solution of alcohol (1 equiv.) in dry dichloromethane at 0 °C was added proton sponge 
(3-8 equiv.), followed by trimethyloxonium tetrafluoroborate (2.5-4 equiv.). The suspension 
was warmed to room temperature and stirred for 16 h. The reaction mixture was quenched 
with aqueous ammonium chloride (saturated) and diluted with dichloromethane. The reaction 
mixture was partitioned and the aqueous phase extracted with dichloromethane. The organic 
layers were combined and washed with aqueous hydrochloric acid (2M) and brine. The 
organic layer was dried over MgSO4, filtered, and the solvent removed under reduced 
pressure. The residue was uptaken in dichloromethane and evaporated onto silica gel. 
Purification by silica gel chromatography, eluting with ethyl acetate and light petroleum 
(10:90) provided the desired methyl ether. 
 
Ester hydrolysis for non-quaternary carbon compounds 
To a solution of ester (1 equiv.) in THF:methanol:water (4:1:1) was added lithium hydroxide 
monohydrate (10 equiv.) the suspension was stirred at room temperature for 16 h. The 
reaction mixture was washed with ether. The aqueous layer was acidified to pH = 1 with 
aqueous hydrochloric acid (2M) and extracted with ethyl acetate. The organic layers were 
combined and washed with brine, dried over MgSO4, filtered and the solvent removed under 
reduced pressure to give the desired carboxylic acid. 
Ester hydrolysis for quaternary carbon compounds 
To a solution of ester 31 (1 equiv.) in dioxane:H2O (4:1) was added lithium hydroxide 
monohydrate (10 equiv.) the reaction mixture was heated under reflux for 16 h. The reaction 
mixture was cooled to room temperature and washed with ether. The aqueous layer was 
acidified to pH = 1 with aqueous hydrochloric acid (2M) and extracted with ethyl acetate. The 
organic layers were combined and washed with brine, dried over MgSO4, filtered and the 
solvent removed under reduced pressure to give the desired carboxylic acid. 
Amide formation 
To a solution of carboxylic acid  (1 equiv.) in dry DMF at 0 °C was added 4-
bromobenzylamine hydrochloride (1.5 equiv.) and diisopropylethylamine (3 equiv.). The 
reaction mixture was stirred for 15 min and HATU (1.5 equiv) was added. The reaction 
mixture was warmed to room temperature and stirred for 16 h. Following this time, the solvent 
was removed under reduced pressure and the residue diluted with ethyl acetate and water. 
The organic layer was separated and the aqueous layer extracted with ethyl acetate. The 
organic layers were combined and washed with aqueous hydrochloric acid (2M), aqueous 
sodium carbonate solution (saturated) and brine. The organic layers were dried over MgSO4, 
filtered and the solvent removed under reduced pressure. The residue was uptaken in 
dichloromethane and evaporated onto silica gel. Purification by silica gel chromatography 
provided the desired amide. 
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